World’s First Wearable Doppler Ultrasound Patch Expands to East Coast to Enhance Patient Safety at The Mount Sinai Hospital

Flosonics Medical, the leader in wearable ultrasound for critical care, today announced that The Mount Sinai Hospital has adopted FloPatch, the first wireless Doppler ultrasound device, in its surgical and transplant intensive care units. This milestone marks the company’s first East Coast deployment, expanding its U.S. footprint and reinforcing growing demand for real-time, individualized fluid management in ICUs.

FloPatch is an FDA-cleared, non-invasive wearable device that enables ICU clinicians to perform rapid, repeatable hemodynamic assessments to guide intravenous (IV) fluid management, a critical intervention in post-surgical care. Although fluid boluses are commonly used to treat hypotension after surgery, many patients are not fluid responsive and may face adverse effects from unnecessary fluids, leading to complications and longer hospital stays. Unlike existing tools, which can be time-consuming or invasive, FloPatch delivers real-time blood flow data at the bedside in under three minutes, helping clinicians avoid delays and make more targeted decisions.

“The wireless ultrasound device addresses a longstanding need in critical care for accessible and repeatable assessments to understand a patient’s fluid responsiveness at the bedside,” said John Oropello, MD, Professor of Surgery and Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Transplant ICU at Mount Sinai Hospital. “It allows our team to make timely, physiologically guided decisions in complex, high-acuity situations.”

Since introducing FloPatch in April 2025, Mount Sinai clinicians have used it to bring greater precision to fluid therapy, moving beyond protocolized care to personalized decisions grounded in real-time patient data. According to early internal data at Mount Sinai, 42% of the patients assessed with FloPatch were unresponsive to fluids, a key insight that has helped clinicians tailor treatment to meet the needs of each individual.

“Critical care ultrasound for targeted intravenous volume management is now a Society recommendation, but widespread application is limited by time, training, and inconsistency,” said Jon-Emile Kenny, MD, Chief Medical Officer and co-founder of Flosonics Medical. “We built FloPatch to make ultrasound best practices available not only to physicians, but to nurses, nurse practitioners, physician assistants, and others involved in frontline decision-making. As the first hospital on the East Coast to adopt wearable ultrasound technology, Mount Sinai strengthens its reputation of leadership and innovation in precision medicine.”

Mount Sinai’s adoption of FloPatch signals a broader shift toward precision medicine in critical care. As the first hospital to implement this wearable technology in surgical and transplant ICUs, it is setting a new benchmark for individualized fluid management. Flosonics is proud to lead this innovation and support clinicians coast to coast in delivering safer, smarter care.

About Flosonics Medical: Flosonics Medical is a medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company's mission is to improve patient care and the practice of medicine through technology-enabled solutions and groundbreaking clinical research. For more information, please visit www.flosonicsmedical.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250617212120/en/